Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (161-170 of 193) with videos related to

Pageof 20
Sort By:
Rheumatology (Oxford, England)|December 1, 2021
Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritisAnn-Sophie De Craemer, Thomas Renson, Liselotte Deroo, et al.
Arthritis Care & Research|May 9, 2017
Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled StudyMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Annals of the Rheumatic Diseases|November 9, 2024
Shared lung and joint T cell repertoire in early rheumatoid arthritis driven by cigarette smokingKoen Venken, Matthias Jarlborg, Frederik Stevenaert, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2023
Gut Inflammation in Axial Spondyloarthritis Patients is Characterized by a Marked Type 17 Skewed Mucosal Innate-like T Cell SignatureCéline Mortier, Katrien Quintelier, Ann-Sophie De Craemer, et al.
Annals of the Rheumatic Diseases|May 17, 2023
Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritisKoen Venken, Matthias Jarlborg, Tine Decruy, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialPhilip Mease, Laura C Coates, Philip S Helliwell, et al.
Nature Reviews. Rheumatology|November 27, 2025
Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiativeFabian Proft, Andre L Ribeiro, Shikha Singla, et al.
Annals of the Rheumatic Diseases|November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safetyFrank Heldmann, Xenofon Baraliakos, Uta Kiltz, et al.
Annals of the Rheumatic Diseases|January 17, 2023
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trialsDésirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, et al.
Pageof 20

Showing results (161-170 of 193) with videos related to

Sort By:
Pageof 20
Rheumatology (Oxford, England)|December 1, 2021
Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritisAnn-Sophie De Craemer, Thomas Renson, Liselotte Deroo, et al.
Arthritis Care & Research|May 9, 2017
Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled StudyMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Annals of the Rheumatic Diseases|November 9, 2024
Shared lung and joint T cell repertoire in early rheumatoid arthritis driven by cigarette smokingKoen Venken, Matthias Jarlborg, Frederik Stevenaert, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2023
Gut Inflammation in Axial Spondyloarthritis Patients is Characterized by a Marked Type 17 Skewed Mucosal Innate-like T Cell SignatureCéline Mortier, Katrien Quintelier, Ann-Sophie De Craemer, et al.
Annals of the Rheumatic Diseases|May 17, 2023
Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritisKoen Venken, Matthias Jarlborg, Tine Decruy, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialPhilip Mease, Laura C Coates, Philip S Helliwell, et al.
Nature Reviews. Rheumatology|November 27, 2025
Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiativeFabian Proft, Andre L Ribeiro, Shikha Singla, et al.
Annals of the Rheumatic Diseases|November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safetyFrank Heldmann, Xenofon Baraliakos, Uta Kiltz, et al.
Annals of the Rheumatic Diseases|January 17, 2023
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trialsDésirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, et al.
Pageof 20